Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Incannex Healthcare Inc. - Common Stock (NQ: IXHL ) 1.880 +0.100 (+5.62%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Incannex Healthcare Inc. - Common Stock < Previous 1 2 3 4 5 6 7 8 Next > Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More March 07, 2023 Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... Via Benzinga Here Are The Year's Highest Priced Psychedelics Stocks In US Markets March 06, 2023 After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on. Via Benzinga Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use March 03, 2023 Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use Via News Direct Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use March 03, 2023 Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD Joel Latham sits down with Proactive to talk about the development and manufacturing deal it has struck with pharma giant Catalent to produce... Via TheNewswire.com Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials March 03, 2023 Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has... Via Benzinga Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial February 28, 2023 Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients... Via TheNewswire.com Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial February 28, 2023 Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial Via News Direct Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis February 28, 2023 Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients... Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session January 25, 2023 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session January 25, 2023 Via Benzinga Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket January 25, 2023 Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a... Via Benzinga Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results January 18, 2023 Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ: Via Benzinga Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More December 13, 2022 Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session December 08, 2022 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday December 08, 2022 We're starting off the day with a look at the biggest pre-market stock movers that traders will want to watch on Thursday! Via InvestorPlace Incannex Files A Provisional Patent Application Of Its THC-Based IHL-42X For The Treatment Of Obstructive Sleep Apnea December 06, 2022 Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of obstructive sleep apnea (‘OSA’). Via Benzinga Eurofins To Produce Incannex' 2 CBD Medicated Chews For Treatment Of Nicotine And Opioid Addiction Disorders November 28, 2022 Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has engaged multinational contract development and manufacturing organization Eurofins Scientific (OTCPK:ERFSF) to manufacture Incannex’s two... Via Benzinga Incannex Initiates BA/BE Clinical Trial Evaluating IHL-42X In Obstructive Sleep Apnoea November 17, 2022 Cannabis and psychedelics-focused Pharma company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1... Via Benzinga A Global List Of Cannabis Operators And Executives To Keep An Eye On In 2022 And Beyond November 09, 2022 Less than 30 years after Israel became the first nation in the world to allow its citizens to use cannabis for medical purposes, the medical and adult-use cannabis markets have spread across the globe... Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session November 04, 2022 Gainers Incannex Healthcare (NASDAQ:IXHL) shares moved upwards by 30.7% to $5.19 during Friday's pre-market session. The market value of their outstanding shares is at $316.2 million. Via Benzinga Australian Psychedelics: Incannex Business & Financials, New Research Center For Mushrooms & Eating Disorders October 28, 2022 Clinical-stage biopharma company Incannex Healthcare Ltd. (NASDAQ: IXHL) shared its quarterly activities report and appendix 4C for the period ended 30 September 2022, noticeably applying for several... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday October 13, 2022 Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning! Via InvestorPlace Unrivaled Brands & Other Cannabis Operators Just Made Some Key Executive Changes You Should Know About August 19, 2022 As Benzinga Cannabis Capital Conference returns on September 13-14 to Chicago, gathering top CEOs, investors and leaders in the industry, let's scroll through the latest leadership changes within the... Via Benzinga Icannex Taps Ex Pfizer, FDA & Regulatory Affairs Expert August 17, 2022 Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) appointed pharmaceutical executive Robert B. Clark to the board of directors. Via Benzinga Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday August 08, 2022 Gainers Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session July 22, 2022 Via Benzinga Incannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug July 21, 2022 Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary... Via Benzinga Incannex Reveals Clinical Trial Results On Dronabinol-Based Drug For Obstructive Sleep Apnea June 03, 2022 Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet... Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session June 03, 2022 Via Benzinga Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea: Incannex Healthcare Limited (NASDAQ: IXHL) May 24, 2022 Via Get News Exposures Product Safety < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.